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Extended 
Data Fig. 1 
Restriction 
activity and 
surface 
exposure of 
SERINC. 
Extended_D
ata_Fig1_VE
P.jpeg 
a,b, HIV-1 restriction activity of 
DmSERINC compared with human 
SERINC5 and SERINC2. Human 
and DmSERINC proteins with HA 
tags at their C-termini were 
expressed in HEK293T cells with 
two different expression vectors 
(pcDNA and pBJ6) which provide 
high and low expression, 
respectively. Levels of the indicated 
SERINC proteins were assessed by 
Western blotting using an anti-HA 
antibody (uncropped blot images are 
shown in the Source Data) (a) and 
by flow cytometry (b) to detect the 
proteins surface expression (b, top) 
or total expression (b, bottom) using 
an anti-FLAG antibody on non-
permeabilzed and permeabilized 
cells respectively. c, Effect of 
SERINC expression on infectivity 
of HIV-1 produced in HEK293T 
cells transfected to express the 
indicated SERINC-iFLAG-HA and 
Nef-deficient HIV-1NL4-3. (Data 
shown are mean and s.d. of n=4 
technical repeats. Data are provided 
in the Source Data). d, Insertion of 
the FLAG epitope into ECL4 does 
not interfere with the anti-HIV-1 
restriction activity of SERINC5. 
Infectivity of Nef-deficient HIV-
1NL4-3 produced in HEK293T cells 
transfected to express unmodified 
human SERINC5-HA or a variant 
modified by inserting a FLAG tag 
within its ECL4 (SERINC5-iFLAG-
HA). Two different expression 
vectors (pcDNA and pBJ6) were 
used in order to obtain high and low 
SERINC5 expression as shown 
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above (Data shown are mean and 
s.d. of n=4 technical repeats. Data 
are provided in the Source Data). e, 
Effect of ECL5 SERINC5 variants 
on HIV-1 susceptibility to 
neutralization. IC50 values derived 
from fitted sigmoidal curves shown 
in figure 4, obtained from 
quadruplicate repeats using 
antibodies 2F5 and 4E10 on Nef-
defective HIV-1NL4-3 pseudotyped 
with the envelope glycoprotein 
derived from HIV-1JR-FL, produced 
by transfecting HEK293T cells with 
the indicated PBJ5-SERINC5-
iFLAG-HA variants or the empty 
vector control (Data shown are 
mean and 95% confidence interval 
of n=4 technical repeats. Data are 
provided in the Source Data). 
Extended 
Data Fig. 2 
Human 
SERINC5 
purification 
and EM 
Extended_D
ata_Fig2_VE
P.jpeg 
a, Size exclusion chromatography 
profile. b, Left: SDS-PAGE analysis 
of resulting fractions; right: 
cleavage of TwinStrep tag and 
deglycosylation (uncropped gel 
images are shown in the Source 
Data). c, Sample micrograph of 
negatively stained particles. d, 
Representative 2D class averages. e, 
Schematic of image processing and 
reconstruction of the human 
SERINC5 cryo-EM structure. 
Details are given in Extended 
Methods. f, Left: Gold standard FSC 
curve for the cryo-EM 
reconstruction of SERINC5, Right: 
Euler angle distribution plot for 
particles included in the final 3D 
reconstruction; 3DFCS reports a 
sphericity of 0.976. g, The map 
colored according to local resolution 
estimated with blocres.   
 
Extended 
Data Fig. 3 
DmSERINC 
purification 
and EM. 
Extended_D
ata_Fig3_VE
P.jpeg 
a, Left: chromatography profile of 
DmSERINC on a Superdex 200 
column; the blue arrow highlights 
elution of the material, which was 
re-injected onto the column. Right: 
elution profile of hexameric 
DmSERINC. b, Left: SDS PAGE 
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analysis of chromatography 
fractions; Right: purified hexamer 
(first 4 lanes) and monomer (last 
four lanes) uncleaved vs cleaved 
sample showing higher oligomeric 
states in hexamer sample shift upon 
cleavage of the C-terminal 
TwinStrep tag (uncropped gel 
images are shown in the Source 
Data). c, Sample micrograph of 
negatively stained DmSERINC 
sample from 9.8-ml peak. d, 2D 
class averages of negatively stained 
DmSERINC. e, Schematic of image 
processing and 3D reconstruction of 
the DmSERINC hexamer. Volumes 
are shown at two contour levels, 
towards the protein level in solid 
white and the outline of the 
detergent micelle in transparent 
grey. Details of the image 
processing and reconstruction are 
given in Extended Methods. f, Left: 
Gold-standard FSC curve for the 
refined DmSERINC cryo-EM map. 
f, Right: Euler angle distribution 
plot for aligned particles 
contributing to the 3D 
reconstruction; bar lengths and color 
(blue low, red high) correspond to 
numbers of particles in 
corresponding orientations. g, Cryo-
EM map colored according to local 
resolution estimated with blocres 
and shown at high (left) and low 
(right) contour levels. h, Cryo-EM 
maps of the asymmetrical 
DmSERINC hexamer 
(corresponding to 3D classes 3 and 
8 in Extended Data Fig. 3e) with 
fitted model: viewed down 6-fold 
axis (top)  or from side (bottom).  
The map is contoured to highlight 
the protein components (right) or the 
detergent micelle (left). 
 
Extended 
Data Fig. 4 
Structural 
features of 
DmSERINC 
Extended_D
ata_Fig4_VE
P.jpeg 
a, Transmembrane topology 
diagram of DmSERINC structure 
with residues not resolved in the 
cryo-EM map shaded grey. b, 
 4
Topology diagram of the SERINC 
protein fold, colored as in Fig. 1b. 
ECLs and ICLs are labelled along 
with disulphide bonds and 
subdomains A and B. c, Scatter plot 
of top 500 results from analysis 
using Dali server, showing numbers 
of aligned residues versus root mean 
square deviations (Å) of Cα atom 
positions. d, DmSERINC hexamer 
colored by conservation; Guillemet 
indicates the viewpoint on the 
protomer-protomer interface labeled 
with asterisk that is shown in the 
sideview on the right. e, Examples 
of DmSERINC cryo-EM map with 
fitted model. f, Two disulphide 
bonds identified on the extracellular 
side of DmSERINC. Left:  Cryo-EM 
map showing profile of Cys71-
Cys91 disulphide bond within 
ECL1. Right: Cryo-EM map 
showing profile of Cys238-Cys299 
disulphide bond between ECL3 and 
ECL4. Thermostability of the 
DmSERINC hexamer (g), monomer 
(h), and SERINC5 (i) with the 
addition of reducing agents (0.5 mM 
DTT and 0.5 mM TCEP); data 
shown are mean and s.d. n=3-4 
technical repeats, data are provided 
in source data. j, Molecular dynamic 
simulations of solvation. Left top: 
Density analysis of waters (blue 
surface) around DmSERINC (grey 
cartoon) in one repeat of atomistic 
230-ns simulation. Left bottom: 
Water density shown as a 2D 
heatmap slice. Right: DmSERINC 
residues implicated in controlling 
water wire highlighted in green. 
 
Extended 
Data Fig. 5 
Lipidomics of 
DmSERINC 
structure 
Extended_D
ata_Fig5_VE
P.jpeg 
a, Cryo-EM map features of 
DmSERINC displaying similarities 
with cardiolipin viewed with (right) 
and without (left) coordinates built, 
from two angles. b, Positions of the 
tentative cardiolipin sandwiched 
between the protomers of the 
hexamer.  c-e,  Identification of 
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lipids associated with DmSERINC 
by mass spectrometry: c, Lipidomics 
LC-MS analysis of hexameric 
DmSERINC5 purified from yeast 
cells. Ions corresponding to 
phospholipids (PE, PC, PI) and 
cardiolipin compositions are 
indicated. d, Structures within each 
lipid class are confirmed by MS/MS 
fragmentation. Neutral loss 
fragments, such as R1COO- and 
R2COO- ions, are diagnostic for PE, 
PC, PI and cardiolipin (CL). e, 
Native mass spectra of DmSERINC 
monomers (10+ to 15+ charge state 
distribution) isolated from LMNG 
micelles spiked with PC, PG, PE or 
CL lipids added at a 1:1 molar ratio. 
Up to two equivalents of bound CL 
were observed whereas no distinct 
binding was detected for PC, PG, or 
PE. 
Extended 
Data Fig. 6 
Lipid 
screening 
Extended_D
ata_Fig6_VE
P.jpeg 
a, Lipid binding groove apparent in 
DmSERINC structure, top left: 
Surface representation of 
DmSERINC monomer revealing a 
groove formed between TMs 5, 7, 8 
and 4. top right: Lipid moiety 
modeled into the groove, shown in 
spheres, illustrating complementary 
size, shape and location for lipid 
binding. bottom left: Cartoon 
representation of the same view with 
helices labelled and colored as Fig. 
1b. bottom right: Cartoon 
representation with lipid shown in 
stick format. b, Cryo-EM map has 
lipid-like features in this groove, 
left: map with PS modelled in, right: 
map carved to 2.5 Å around the 
modelled PS to highlight the lipid-
like map features. e.  View of 
DmSERINC in a POPC membrane, 
following 215 ns of atomistic 
simulation. The protein is shown as 
blue cartoon and transparent surface, 
and the POPC lipids as red, orange 
and grey spheres. Lipids in front of 
the protein have been removed to 
reveal how the protein sits in the 
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membrane. d, Post 215 ns view 
of DmSERINC from atomistic MD 
simulation, showing a POPC lipid 
bound to the groove between TM 5 
and 8. The protein is shown in white 
cartoon, the lipid in green, red and 
gold spheres. Note that this lipid 
remains bound for the full 
simulation.  e-g, Lipid 
thermostability assay. e, Change in 
thermostability of DmSERINC 
hexamer upon the addition of 
specific lipid. f, Change in 
thermostability of DmSERINC 
monomer upon the addition of a 
specific lipid; g, Change in 
thermostability of SERINC5 upon 
the addition of a specific lipid 
(select sample of lipids). Data 
shown in e-f are mean and s.d. of 3-
6 technical repeats, data are 
provided in Source Data. 
Extended 
Data Fig. 7 
HDX of lipid 
interactions 
with 
DmSERINC 
Extended_D
ata_Fig7_VE
P.jpg 
a, Left:  Peptide coverage of 
DmSERINC monomer for HDX. 
Right: Structure of DmSERINC 
(with undefined loops modeled in 
using SWISS MODEL) with 
coverage highlighted in blue. b-e, 
HDX profile of purified monomeric 
DmSERINC in LMNG micelles 
prior to (b) or after spiking with 
exogenous DPPS (c), sulfatides (d), 
or PC (e) Peptide residue numbers 
are shown on the x-axis. f, Protected 
regions determined by HDX 
mapped onto the DmSERINC 
structure and highlighted in red 
(with undefined loops modelled in 
using SWISS MODEL). g, surface 
representation of DmSERINC 
structure colored as in Fig. 1b. with 
protected regions highlighted in red. 
 
Extended 
Data Fig. 8 
Juxtaposition 
of SERINC5 
and the 
trimeric 
HIV-1 
envelope 
spike. 
Extended_D
ata_Fig8_VE
P.jpeg 
The model of human SERINC5 is 
shown in grey cartoons with 
residues important for restriction 
highlighted in blue and modeled 
loops in white transparent. The 
illustrative model of full-length 
trimeric HIV-1 Env was assembled 
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The human integral membrane protein SERINC5 potently restricts HIV-1 33 
infectivity and sensitises the virus to antibody-mediated neutralisation. Here, 34 
using cryo-electron microscopy, we determined the structures of human 35 
SERINC5 and its ortholog from Drosophila melanogaster at sub-nm and near-36 
atomic resolution, respectively. The structures reveal a novel fold comprised of 37 
ten transmembrane helices organised into two subdomains and bisected by a 38 
long diagonal helix. A lipid binding groove and clusters of conserved residues 39 
highlight potential functional sites. A structure-based mutagenesis scan 40 
identified surface-exposed regions and the interface between the subdomains of 41 
SERINC5 as critical for HIV-1 restriction activity. The same regions are also 42 
important for viral sensitisation to neutralising antibodies, directly linking the 43 
antiviral activity of SERINC5 with remodelling of the HIV-1 envelope 44 
glycoprotein. 45 
 46 
Host organisms employ a range of mechanisms to impede replication of pathogens, 47 
and the latter evolve countermeasures to circumvent the innate immunity of their 48 
hosts1. One such antagonistic interaction involves the human transmembrane protein 49 
SERINC5, which when incorporated into budding HIV-1 virions, can strongly inhibit 50 
their subsequent entry into target cells2,3. To negate the effect of SERINC5, HIV-1 51 
encodes the endocytic adaptor protein Nef, which redirects this restriction factor, 52 
normally present in the plasma membrane, to endosomal compartments, thereby 53 
preventing its inclusion into budding viral particles2,3. The ability to ablate plasma 54 
membrane-associated SERINC proteins is conserved among retroviruses2-5, 55 
suggesting a strong evolutionary pressure to prevent virion incorporation of these host 56 
factors. Exclusive to eukaryotes, SERINCs share high amino acid identity among 57 
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themselves (Supplementary Table 1) but lack homology to any other known protein 58 
family. The term SERINC was coined after the proposed role of serine incorporation 59 
into membranes during lipid biosynthesis6. However, this function has so far not 60 
found independent confirmation, and mass spectrometry analyses failed to detect 61 
SERINC-dependent changes in cellular or virion lipid composition7,8. The human 62 
genome encodes five SERINC paralogs, of which one, SERINC2, lacks the HIV-1 63 
restriction activity9,10. Recent studies highlighted associations of SERINC genes with 64 
autism11, borderline personality disorders12, alcohol dependence13, and 65 
cancerogensis14-17.  66 
SERINC5 inhibits HIV-1 infectivity by specifically interfering with viral 67 
entry2,3, although the precise mode of restriction remains enigmatic. HIV-1 particles 68 
assemble at lipid rafts within plasma membrane and utilize host endosomal sorting 69 
complexes required for transport (ESCRT) machinery to bud from the infected cell 70 
(reviewed in ref. 18). Following their maturation, virions infect target cells through 71 
fusion of the viral and host cell membranes. This process is orchestrated by the viral 72 
envelope glycoprotein (Env), which is a trimer comprised of the surface glycoprotein 73 
gp120 and the single-pass transmembrane subunit gp41, (gp41-gp120)3. A series of 74 
conformational changes within HIV-1 Env, triggered by the interaction of gp120 with 75 
CD4 and a co-receptor (CCR5 or CXCR4) on surface of a target cell, lead to the 76 
insertion of the gp41 fusion peptide into the target cell plasma membrane. The 77 
subsequent collapse of the gp41 structure into a 6-helix bundle is believed to initiate 78 
the fusion of viral and host cell membranes19. HIV-1 Env is highly variable, and 79 
individual viral isolates display vastly different sensitivities to neutralizing antibodies 80 
and restriction by SERINC5. Thus, while SERINC5 can ablate infectivity of the 81 
HIV-1 clone NL4-3, it has only a modest effect on the tier 2 and 3 HIV-1 isolates, 82 
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such as JRFL2,3,10,20,21. Nevertheless, JRFL becomes considerably more sensitive to 83 
some neutralizing antibodies and the CCR5 antagonist Maraviroc in the presence of 84 
SERINC5, suggesting that the restriction factor exerts a direct effect on the 85 
conformation of HIV-1 Env10,20. 86 
Here we present the three-dimensional structure of a SERINC family member 87 
to near-atomic resolution and show that the observed conformation is consistent with 88 
that of human SERINC5, which we resolved at sub-nm resolution.  Additionally, 89 
using an extensive panel of amino acid substitutions, we identify the regions of 90 
SERINC5 that are critical for its antiviral activities. 91 
 92 
Results 93 
Structure determination of Drosophila melanogaster SERINC. The fly possesses a 94 
single SERINC ortholog (referred to here as DmSERINC, and also known as TMS1) 95 
that shares 36% amino acid sequence identity with human SERINC5 (Supplementary 96 
Table 1). Ectopic expression of DmSERINC during production of Nef-deficient HIV-97 
1 virions strongly suppressed their infectivity (Extended Data Fig. 1 a-c), confirming 98 
conservation of functional restriction by the insect ortholog. To structurally 99 
characterise the SERINC family of proteins, we produced recombinant human 100 
SERINC5 and DmSERINC in human and yeast cells, respectively. When subjected to 101 
chromatography through a 24-ml Superdex-200 sizing column, SERINC5 migrated as 102 
a single peak with elution volume of 12 ml. Imaging negatively-stained material from 103 
this peak revealed featureless micelles, which failed to produce discrete 2D averages 104 
(Extended Data Fig. 2a-d). By contrast, separation of DmSERINC resulted in an 105 
additional species eluting at 9.8 ml, containing well-defined assemblies with 106 
prominent six-fold symmetry (Extended Data Fig. 3a-d). Encouraged by these results, 107 
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we acquired micrograph movies of frozen-hydrated DmSERINC from this fraction. 108 
Image processing of single particles resulted in a 3D reconstruction to an overall 109 
resolution of 3.3 Å with a local resolution of 2.8-3 Å for the majority of the protein 110 
(Extended Data Fig. 3e-g). Atomic coordinates were built ab initio into the cryo-EM 111 
map revealing the details of the homo-hexameric DmSERINC structure (Fig. 1a,b, 112 
Table 1 and Supplementary Video 1).  113 
Each of the six identical DmSERINC subunits consists of ten transmembrane 114 
helices (TM) arranged into two subdomains revealing a tertiary fold that is ~35 Å by 115 
~50 Å in the membrane plane and ~50 Å traversing the membrane (Fig. 1b). A 39-116 
residue-long α-helix (TM4) spans the membrane diagonally intersecting subdomain A 117 
(TM1, TM2, TM3, TM9) and subdomain B (TM5, TM6, TM7 and TM10). A shorter 118 
diagonal α-helix TM8 crosses back from subdomain B to A, forming an asymmetrical 119 
cross with TM4 in the centre. Two disulphide bonds are identified on the extracellular 120 
side: one within extracellular loop (ECL) 1 (Cys71-Cys95, conserved in most species 121 
except plants and some lower eukaryotes) and one between ECL3 and ECL4 122 
(Cys238-Cys299, conserved throughout the SERINC family) (Fig. 1b, Extended Data 123 
Fig. 4f, Supplementary Table 1 and Supplementary Video 1). Concordantly, exposure 124 
of DmSERINC and SERINC5 to reducing agents decreased their thermostability 125 
(Extended Data Fig. 4g-i). The disulphide bonds and the location of ECL4, the 126 
equivalent of which harbours glycosylated Asn294 in SERINC522, confirms the 127 
assigned orientation within the plasma membrane, with both the N- and C-termini of 128 
the protein residing in the cytoplasm (Fig. 1b, Supplementary Table 1 and Extended 129 
Data Fig. 4a,b). 130 
A query of the wwPDB using the Dali server23 did not identify proteins 131 
sharing extensive structural similarity with DmSERINC (Extended Data Fig. 4c). 132 
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Accordingly, the DmSERINC structure represents a novel membrane protein fold. We 133 
considered if the hexameric arrangement of DmSERINC was characteristic of the 134 
SERINC family. Protomer interface contacts bury 958 Å2, comprising only 5.3% of 135 
the total DmSERINC monomer surface. Furthermore, the interfaces are devoid of 136 
conserved amino acid residues (Extended Data Fig. 4d) and are largely lipid-137 
mediated. Based on the cryo-EM map, we assigned one of the protomer-bridging 138 
lipids as cardiolipin and confirmed its presence in our DmSERINC preparations by 139 
mass spectrometry (Extended Data Fig. 5). Consistent with the structure, we observed 140 
binding of up to two molecules of cardiolipin per DmSERINC monomer (Extended 141 
Data Fig. 5e). We conclude that while the hexameric state of DmSERINC made it 142 
conducive to high-resolution cryo-EM that afforded de novo model building, it may 143 
not be conserved throughout the protein family. Accordingly, we readdressed 144 
structural characterisation of human SERINC5 (see below). 145 
 146 
Potential functional features of SERINC. Exploring the DmSERINC structure 147 
further, we identified clusters of highly-conserved residues, which may represent 148 
functional sites in the fold (Fig. 2). Within subdomain A, lipid-buried Lys143 149 
assembles with Tyr42, Gln136, Trp140, Tyr395, and His401 to form a small pocket at 150 
the membrane-cytosol interface (Fig. 2, bottom). At the extracellular side of the 151 
structure, Gln181, Tyr282, Tyr285, Ser289, Lys438, and Thr414 line a hydrophilic 152 
cleft between the two subdomains that is corked by Trp418. This crevice extends half-153 
way through the lipid bilayer, where it is plugged by invariant Phe177 (Fig. 2, top). 154 
Molecular dynamics simulations of lipid-embedded DmSERINC suggested that 155 
solvent molecules can freely enter the space between the subdomains (Extended Data 156 
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Fig. 4j). Searching structural databases with ProFunc24 did not reveal similarity of 157 
either conserved pocket to any of the known functional sites.  158 
The surface of subdomain B features an elongated groove formed by TM5, 7, 159 
8 and the C-terminal end of TM4, which is an appropriate size, shape, and location to 160 
accommodate a lipid moiety, potentially allowing a head group to access the 161 
hydrophilic cleft between the subdomains (Extended Data Fig. 6a,b). When we 162 
embedded the protein structure in a lipid bilayer in silico, the groove became readily 163 
occupied by lipids during molecular dynamics (MD) simulations, and the cryo-EM 164 
map revealed presence of an acyl chain bound at this site (Extended Data Fig. 6c,d). 165 
We conducted a screen of lipids and found that addition of phosphatidylserine, 166 
cholesterol or sulfatide increased DmSERINC and SERINC5 protein thermostability, 167 
while cardiolipin stabilised DmSERINC only (Extended Data Fig. 6e-g). Moreover, 168 
hydrogen/deuterium exchange (HDX) experiments with DmSERINC revealed that 169 
phosphatidylserine affected isotope exchange around the potential lipid binding 170 
groove in subdomain B (Extended Data Fig. 7). 171 
 172 
The structure of human SERINC5. Composed of two subdomains, the DmSERINC 173 
structure is suggestive of conformational flexibility. To determine if the conformation 174 
observed in DmSERINC represents that of the bona fide HIV-1 restriction factor, we 175 
imaged SERINC5 in detergent micelles doped with phosphatidylserine, which was 176 
found to increase thermostability of the protein (Extended Data Fig. 6g). To aid in 177 
single particle image alignment of this 51 kDa protein, we acquired cryo-EM data in 178 
the presence of the antigen binding fragment (Fab) of a monoclonal antibody that 179 
recognizes SERINC5 ECL4. The resulting 3D reconstruction at a local resolution of 180 
6.5-7 Å contains a single molecule of SERINC5 in a conformation very similar to that 181 
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of DmSERINC protomers within the hexamer (Fig. 3, Extended Data Fig. 2 and 182 
Supplementary Video 2), leading us to conclude that the conformation we observe in 183 
the DmSERINC structure is also adopted by human SERINC5. 184 
 185 
Mapping SERINC5 regions critical for the antiviral activity. To identify regions 186 
of SERINC5 involved in HIV-1 restriction, we conducted an extensive mutagenesis 187 
screen, informed by the structure and amino acid sequence conservation with 188 
SERINC2, which lacks the HIV-1 restriction activity9,10. The mutations were 189 
introduced into constructs designed to express SERINC5 harbouring a FLAG epitope 190 
implanted within ECL4. This modification enabled surface exposure measurements of 191 
the modified proteins by flow cytometry without interfering with restriction activity 192 
(Extended Data Fig. 1d). In total, ninety-four SERINC5 mutants were tested for the 193 
ability to inhibit infectivity of Nef-negative HIV-1 (Fig. 4, Supplementary Table 2). 194 
The loss-of-function mutants clustered into two classes. The first class, comprising 195 
variants that also failed to localise to the plasma membrane, harboured the majority of 196 
mutants at highly conserved or invariant positions across the entire SERINC family, 197 
such as substitutions of Lys130, Phe165, Tyr388, His394, Trp411, Lys433, and 198 
Tyr444 (Fig. 4a). The second class of restriction-defective mutants retained the ability 199 
to localise to the plasma membrane. The majority of these carried substitutions within 200 
the ECLs or in proximity to the interface between the subdomains (Fig. 4b, d). This 201 
class included variants with substitutions within ECL5, such as a partial swap for the 202 
equivalent loop from SERINC2 (the mutant designated ECL5B), and double mutants 203 
NY413KP and IE419KM.  204 
Next, we tested a representative subset of SERINC5 variants for incorporation 205 
into HIV-1 particles. As can be expected, class 1 mutants with severe defects in 206 
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surface expression (K130A and K433A) were deficient for glycosylation and failed to 207 
incorporate into virions (Fig. 4c), explaining their inability to restrict infection. In 208 
contrast, class 2 mutants that were competent for plasma membrane localization 209 
incorporated into viral particles (Fig. 4c). To test the ability of these mutants to 210 
remodel HIV-1 Env, we pseudotyped Nef-negative HIV-1 particles with the tier-2 211 
glycoprotein JRFL, which is substantially resistant to restriction by SERINC53. In 212 
agreement with published observations10,20,25, the virus produced in the presence of 213 
WT SERINC5 displayed enhanced sensitivity to neutralisation by the monoclonal 214 
antibodies 4E10 and 2F5, both of which target the highly-conserved membrane 215 
external proximal region (MPER) of HIV-1 Env (Fig. 4e). Remarkably, class 2 216 
SERINC5 mutants were substantially compromised in their ability to sensitize the 217 
virus to neutralization (Fig. 4e). Thus, despite incorporation into virions, class 2 218 
mutants are defective for both of the antiviral activities.  219 
 220 
Discussion  221 
The conserved cellular functions of SERINCs remain unclear, underscoring the 222 
difficulty in determining structure-function relationships from first principles. Further 223 
studies will be required to test the functional significance of phosphatidylserine, 224 
sulfatide and/or cholesterol binding in biological functions of SERINC proteins. 225 
Affinity for cholesterol and/or exposed phosphatidylserine could help explain the 226 
association of SERINC5 with lipid rafts9,26 and ultimately incorporation of the protein 227 
into budding virions.  228 
The failure of class 1 SERINC5 mutants to inhibit HIV-1 infectivity strongly 229 
argues that the protein must be located at the plasma membrane to exert its antiviral 230 
activity. Intriguingly, despite virion incorporation, class 2 mutants were deficient for 231 
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both restriction and sensitization to neutralizing antibodies. The congruence of these 232 
antiviral activities suggests a specific interaction resulting in the conformational 233 
remodelling of surface-exposed regions of HIV-1 Env. The involvement of the ECLs 234 
and the interface between the subdomains in restriction suggests that the restriction 235 
depends on a specific conformation of SERINC5 and strongly indicates that this 236 
activity takes place on the external surface of the virion.  237 
For illustrative purposes, we modelled the complete HIV-1 Env trimer using 238 
recent partial experimental structures27,28 (Extended Data Fig. 8a). In contrast to the 239 
extended viral spike, SERINC5 is almost entirely membrane embedded, poised to 240 
reach only the membrane proximal and/or embedded regions of Env (Extended Data 241 
Fig. 8a). Intriguingly, the spacing between ECL3 and ECL5 of SERINC5, both of 242 
which are important for the antiviral activities, matches that between the MPER 243 
regions within the Env trimer (Extended Data Fig. 8b,c). We speculate that interaction 244 
with the neighbouring MPER domains could explain both the inhibition of HIV-1 245 
fusion and the sensitization to 2F5 and 4E10 antibodies by SERINC5. This hypothesis 246 
is consistent with the genetic studies that mapped the determinants of SERINC5 247 
sensitivity to the variable loops in gp12020,29, as amino acid changes in the variable 248 
loops can modulate the accessibility of MPER30. Moreover, the interaction with CD4, 249 
which triggers an open HIV-1 Env conformation and increases MPER accessibility31, 250 
rendered tier 2 and 3 viral isolates sensitive to restriction by SERINC521. At present, 251 
we cannot exclude other possibilities, such as interactions with viral glycans and/or 252 
conformational movements of the spike that would enable direct SERINC5 contacts 253 
with gp120. Our structures and extensive functional data provide the initial insights at 254 
the molecular level of SERINC proteins and their ability to restrict HIV-1 infection, 255 
 20
warranting further research to clarify the molecular basis of the engagement between 256 
the host factor and HIV-1 Env.  257 
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Figure Legends 302 
Figure 1 | The structure of DmSERINC. a, Cryo-EM map of the hexamer with each 303 
protomer individually colored; the map was Gaussian filtered with a standard 304 
deviation of 5 Å to represent the detergent micelle, grey (left) and a cartoon 305 
representation of the DmSERINC hexamer (right). b, Detailed representation of an 306 
isolated monomer, colored in green to dark blue gradient from N- to C-terminus with 307 
transmembrane alpha helices numbered and loops labelled (intracellular loops (ICL) 308 
and extracellular loops (ECL)). The position of the lipid groove is indicated by a grey 309 
rectangle.  Disulphide bonds are labelled and shown in stick format. The outer and 310 
inner plasma membrane surfaces are depicted as chocolate and olive dotted planes, 311 
respectively.  312 
 313 
Figure 2 | Potential functional sites identified in SERINC structure. Sequence 314 
conservation mapped onto the DmSERINC structure, with invariant residues in dark 315 
blue and most variable in red; the outer and inner plasma membrane surfaces are 316 
depicted as chocolate and olive dotted planes, respectively. The insets show details of 317 
the hydrophilic cleft between the subdomains (top) and a highly conserved pocket 318 
(bottom). 319 
 320 
Figure 3 | Structure of human SERINC5 bound to Fab. The cryo-EM map is 321 
shown as a semi-transparent white surface, with fitted atomic models of DmSERINC 322 
(cartoons colored as in Fig. 1b) and Fab (purple cartoons). Top view shows 323 
transmembrane helices traversing the detergent micelle and bottom view is a 324 
perpendicular slice showing SERINC5 surrounded by the micelle. 325 
 326 
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Figure 4 | SERINC5 residues critical for HIV-1 restriction activity. a and b, 327 
restriction activity and surface expression of human SERINC5 variants relative to 328 
SERINC5 wt (data shown are mean and s.d. of n=3 independent experiments). a, 329 
Class 1 amino acid substitutions interfere with Nef-defective HIV-1NL4-3 restriction 330 
and surface expression. b, Class 2 amino acid substitutions do not affect surface 331 
expression but compromise Nef-defective HIV-1 restriction. c, SERINC5 332 
incorporation into virion particles. Immunoblots of Nef-defective HIV-1 particles and 333 
corresponding producer cell lysates expressing the indicated SERINC5 variants. The 334 
right-most lane contains a Gag-defective provirus control. Arrowheads and asterisks 335 
indicate migration position of glycosylated and non-glycosylated SERINC5, 336 
respectively. Note the selective incorporation of the glycosylated form into viral 337 
particles22 d, Class 1 and 2 residues mapped onto a model of SERINC5, in red and 338 
blue, respectively. e, Neutralisation of Nef-deficient HIV-1NL4-3 carrying the JRFL 339 
envelope by 2F5 and 4E10 monoclonal antibodies. Residual infectivity is relative to 340 
that of untreated viruses (n=4, mean ± 95% confidence interval, technical repeats), 341 
IC50 values are shown in Extended Data Fig. 1e. Uncropped images for panel c and 342 
data for graphs a, b and e are available as Source Data. 343 
 344 
 345 
 346 
 347 
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 350 
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 352 
 353 
Table 1. Cryo-EM data collection, refinement and validation statistics 354 
 DmSERINC
(EMD-10279, PDB 
6SP2) 
SERINC5
(EMD-10277) 
Data collection and 
processing 
  
Magnification 36,232 128,440 
Voltage (kV) 300 300
Electron exposure (e–/Å2) 50 33.6
Defocus range (μm) -1.6 to -4 -1.6 to -4
Pixel size (Å) 1.38 1.09
Symmetry imposed C6 C1
Initial particle images (no.) 1,857,080 2,502,546
Final particle images (no.) 159,252 270,151
Map resolution (Å) 3.3 7.1
    FSC threshold 0.143 0.143
Map resolution range (Å) 2.8-50.0 6.5-50
 
Refinement 
Model resolution (Å) 3.3
    FSC threshold 0.143
Model resolution range (Å) 2.8-4.0
Map sharpening B factor (Å2) -186.2
Model composition 
    Nonhydrogen atoms 18,498
    Protein residues 2,190
    Ligands CDL:6, LMN:12, 
P5S:6 
B factors (Å2) 
    Protein 150.59
    Ligand 163.13
R.m.s. deviations 
    Bond lengths (Å) 0.004
    Bond angles (°) 0.72
 
Validation 
MolProbity score 1.77
Clashscore 8.22
Poor rotamers (%) 0.0
Ramachandran plot 
    Favored (%) 95.28
    Allowed (%) 4.72
    Disallowed (%) 0
 355 
 356 
 357 
 358 
  359 
 25
References 360 
 361 
1. Duggal, N.K. & Emerman, M. Evolutionary conflicts between viruses and 362 
restriction factors shape immunity. Nat Rev Immunol 12, 687-95 (2012). 363 
2. Rosa, A. et al. HIV-1 Nef promotes infection by excluding SERINC5 from 364 
virion incorporation. Nature 526, 212-7 (2015). 365 
3. Usami, Y., Wu, Y. & Gottlinger, H.G. SERINC3 and SERINC5 restrict HIV-1 366 
infectivity and are counteracted by Nef. Nature 526, 218-23 (2015). 367 
4. Chande, A. et al. S2 from equine infectious anemia virus is an infectivity 368 
factor which counteracts the retroviral inhibitors SERINC5 and SERINC3. 369 
Proc Natl Acad Sci U S A 113, 13197-13202 (2016). 370 
5. Ahmad, I. et al. The retroviral accessory proteins S2, Nef, and glycoMA use 371 
similar mechanisms for antagonizing the host restriction factor SERINC5. J 372 
Biol Chem 294, 7013-7024 (2019). 373 
6. Inuzuka, M., Hayakawa, M. & Ingi, T. Serinc, an activity-regulated protein 374 
family, incorporates serine into membrane lipid synthesis. J Biol Chem 280, 375 
35776-83 (2005). 376 
7. Trautz, B. et al. The host-cell restriction factor SERINC5 restricts HIV-1 377 
infectivity without altering the lipid composition and organization of viral 378 
particles. J Biol Chem 292, 13702-13713 (2017). 379 
8. Chu, E.P. et al. Disruption of Serinc1, which facilitates serine-derived lipid 380 
synthesis, fails to alter macrophage function, lymphocyte proliferation or 381 
autoimmune disease susceptibility. Mol Immunol 82, 19-33 (2017). 382 
9. Schulte, B. et al. Localization to detergent-resistant membranes and HIV-1 383 
core entry inhibition correlate with HIV-1 restriction by SERINC5. Virology 384 
515, 52-65 (2018). 385 
 26
10. Sood, C., Marin, M., Chande, A., Pizzato, M. & Melikyan, G.B. SERINC5 386 
protein inhibits HIV-1 fusion pore formation by promoting functional 387 
inactivation of envelope glycoproteins. J Biol Chem 292, 6014-6026 (2017). 388 
11. Hnoonual, A. et al. Chromosomal microarray analysis in a cohort of 389 
underrepresented population identifies SERINC2 as a novel candidate gene for 390 
autism spectrum disorder. Sci Rep 7, 12096 (2017). 391 
12. Lubke, G.H. et al. Genome-wide analyses of borderline personality features. 392 
Mol Psychiatry 19, 923-9 (2014). 393 
13. Zuo, L. et al. Rare SERINC2 variants are specific for alcohol dependence in 394 
individuals of European descent. Pharmacogenet Genomics 23, 395-402 395 
(2013). 396 
14. Zeng, Y. et al. SERINC2-knockdown inhibits proliferation, migration and 397 
invasion in lung adenocarcinoma. Oncol Lett 16, 5916-5922 (2018). 398 
15. Bossolasco, M., Veillette, F., Bertrand, R. & Mes-Masson, A.M. Human 399 
TDE1, a TDE1/TMS family member, inhibits apoptosis in vitro and stimulates 400 
in vivo tumorigenesis. Oncogene 25, 4549-58 (2006). 401 
16. Margue, C. et al. New target genes of MITF-induced microRNA-211 402 
contribute to melanoma cell invasion. PLoS One 8, e73473 (2013). 403 
17. Player, A. et al. Identification of TDE2 gene and its expression in non-small 404 
cell lung cancer. Int J Cancer 107, 238-43 (2003). 405 
18. Hurley, J.H. & Cada, A.K. Inside job: how the ESCRTs release HIV-1 from 406 
infected cells. Biochem Soc Trans 46, 1029-1036 (2018). 407 
19. Chen, B. Molecular Mechanism of HIV-1 Entry. Trends Microbiol 27, 878-408 
891 (2019). 409 
 27
20. Beitari, S., Ding, S., Pan, Q., Finzi, A. & Liang, C. Effect of HIV-1 Env on 410 
SERINC5 Antagonism. J Virol 91(2017). 411 
21. Zhang, X. et al. CD4 expression and Env conformation are critical for HIV-1 412 
restriction by SERINC5. J Virol (2019). 413 
22. Sharma, S., Lewinski, M.K. & Guatelli, J. An N-Glycosylated Form of 414 
SERINC5 Is Specifically Incorporated into HIV-1 Virions. J Virol 92(2018). 415 
23. Holm, L. & Sander, C. Dali: a network tool for protein structure comparison. 416 
Trends Biochem Sci 20, 478-80 (1995). 417 
24. Laskowski, R.A. The ProFunc Function Prediction Server. Methods Mol Biol 418 
1611, 75-95 (2017). 419 
25. Lai, R.P. et al. Nef decreases HIV-1 sensitivity to neutralizing antibodies that 420 
target the membrane-proximal external region of TMgp41. PLoS Pathog 7, 421 
e1002442 (2011). 422 
26. Brugger, B. et al. The HIV lipidome: a raft with an unusual composition. Proc 423 
Natl Acad Sci U S A 103, 2641-6 (2006). 424 
27. Fu, Q. et al. Structure of the membrane proximal external region of HIV-1 425 
envelope glycoprotein. Proc Natl Acad Sci U S A 115, E8892-E8899 (2018). 426 
28. Lee, J.H., Ozorowski, G. & Ward, A.B. Cryo-EM structure of a native, fully 427 
glycosylated, cleaved HIV-1 envelope trimer. Science 351, 1043-8 (2016). 428 
29. Usami, Y. & Gottlinger, H. HIV-1 Nef responsiveness is determined by Env 429 
variable regions involved in trimer association and correlates with 430 
neutralization sensitivity. Cell Rep 5, 802-12 (2013). 431 
30. Chakrabarti, B.K. et al. Direct antibody access to the HIV-1 membrane-432 
proximal external region positively correlates with neutralization sensitivity. J 433 
Virol 85, 8217-26 (2011). 434 
 28
31. Ivan, B., Sun, Z., Subbaraman, H., Friedrich, N. & Trkola, A. CD4 occupancy 435 
triggers sequential pre-fusion conformational states of the HIV-1 envelope 436 
trimer with relevance for broadly neutralizing antibody activity. PLoS Biol 17, 437 
e3000114 (2019). 438 
 439 
 440 
 441 
Methods  442 
Protein expression and purification. DmSERINC carrying a C-terminal TwinStrep 443 
tag was over-expressed in S. cerevisiae and solubilised in a buffer containing 1.5% n-444 
dodecyl-β-D-maltoside (DDM, Anatrace). During affinity purification the detergent 445 
was exchanged to 0.05% lauryl maltose neopentyl glycol (LMNG, Anatrace), the 446 
concentration of which was reduced to a minimum for size exclusion 447 
chromatography. Human SERINC5 protein was purified from a stable cell line 448 
adapted to suspension culture following the protocol for DmSERINC with the 449 
addition of 1,2-dipalmitoyl-sn-glycero-3-phosphoserine (DPPS; Echelon Biosciences) 450 
in the sample for cryo-EM. Detailed descriptions are in Supplementary Note 1. 451 
 452 
Generation of the monoclonal antibody and the Fab to SERINC5. A monoclonal 453 
antibody EVG_S5.2 was produced in a single mouse immunised with recombinant 454 
SERINC5. A hybridoma line producing the antibody was expanded, and the Fab 455 
fragment was produced by digestion of the antibody with papain. Detailed 456 
descriptions are in Supplementary Note 1, and the monoclonal antibody is available 457 
from the Centre for AIDS Reagents (CFAR, www.NIBSC.org) for distribution.  458 
 459 
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 460 
Negative-stain EM. Purified DmSERINC and SERINC5 (4 μl of ~0.01 mg/ml) were 461 
applied to glow-discharged carbon-coated 300-mesh copper grids (EM Resolutions) 462 
for 1 min before brief blotting and staining with 2 % (w/v) uranyl acetate. Grids were 463 
imaged on a Tecnai G2 Spirit LaB6 transmission electron microscope (FEI) operating 464 
at 120 keV. Images were collected with an Ultrascan-1000 camera (Gatan) at a 465 
nominal magnification of 30,000× (corresponding to a pixel size of 3.45 Å at the 466 
specimen level), with an average electron dose of 35 e/Å2 and defocus values of -0.5 467 
to -2.0 μm. Particles, picked semi-automatically using EMAN2 Boxer tool32, were 468 
subjected to reference-free 2D classification in Relion-2.0333 or cryoSPARC34. 469 
 470 
Cryo-EM grid preparation and data collection. Four μl of hexameric DmSERINC 471 
at 0.5 mg/ml, freshly isolated by size exclusion chromatography, was applied onto 472 
glow-discharged holey carbon 400-mesh Quantifoil R1.2/1.3 grids (Quantifoil) for 1 473 
min, with 100% humidity at 20°C, before blotting for 3-4 sec and plunge freezing into 474 
liquid ethane using Vitrobot Mark IV (FEI). Data were collected on a Titan Krios 475 
microscope operating at 300 keV and equipped with a Gatan post-column energy 476 
filter, selecting a 20-eV window, on a GIF Quantum K2 direct electron detector 477 
(Gatan) operating in counting mode. A total of 5,807 movies were recorded using 478 
single electron counting mode with a magnified pixel size of 1.38 Å and a defocus 479 
range of -1.6 to -4 μm. The total electron dose was 50 e-/Å2, spread over 30 frames 480 
(Table 1).  481 
Freshly isolated SERINC5 in LMNG micelles supplemented with DPPS and 482 
equimolar amount of Fab was subjected to size exclusion chromatography through a 483 
Superdex 200 Increase 3.2/300 column. Four μl of isolated SERINC5-Fab complex 484 
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was applied onto non-glow discharged C-flat 400-mesh R1.2/1.3 holey carbon grids 485 
(EMS) for 30 sec under 100% humidity at 20oC, blotted for 7 sec, and vitrified by 486 
plunging into liquid ethane using Vitrobot Mark IV. Data were collected on a Titan 487 
Krios microscope at 300 keV equipped with a Falcon 3 detector. A total 7,165 movies 488 
were recorded in single electron counting mode with a pixel size of 1.09 Å and a 489 
defocus range -1.6 to -4 μm, using total electron doze of 33.6 e-/Å2 over 30 frames 490 
(Table 1).  491 
 492 
Cryo-EM image processing and 3D reconstruction. Micrograph movies were 493 
aligned with dose weighting applied as implemented in MotionCor235 and the contrast 494 
transfer function (CTF) parameters were estimated from the frame sums using Gctf-495 
v1.0636. Movies exhibiting ice contamination were discarded at this stage, leaving 496 
4,238 (DmSERINC) and 7,021 (SERINC5-Fab complex) movies for further 497 
processing. A sub-set of particles semi-automatically picked in EMAN2 Boxer32 were 498 
used to generate the starting 2D class averages, which, upon low-pass filtering to 20 499 
Å, served as templates for auto-picking of the entire dataset (Extended Data Fig. 3e). 500 
The initial DmSERINC particle dataset was picked with Relion-2.133 resulting 501 
in 1,857,080 particles. Reference-free 2D classification was performed in cryoSPARC 502 
using 40 online-EM iterations into 200 classes. Particles belonging to well-defined 2D 503 
classes exhibiting secondary structure elements (717,011 particles) were selected for 504 
further processing. The starting model for 3D classifications was obtained using ab 505 
initio mode of cryoSPARC. 3D classification was carried out using Relion-2.1 into 9 506 
classes without applying symmetry; the hexamer class (159,252 particles) was in 507 
silico purified from other states. The final 3D reconstruction was obtained using non-508 
uniform refinement as implemented in cryoSPARC2 with C6 symmetry applied.  509 
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Classes containing asymmetrical hexamers (classes 3 and 8; Extended Data 510 
Fig. 3e) were investigated further, implementing C1 symmetry, to determine any 511 
structural rearrangements compared with the hexamer. The asymmetrical hexamers 512 
exhibited the exact same secondary structure conformations as the hexamer however 513 
were lacking some of the detergent micelle on one side (Extended Data Fig. 3h). 514 
Dimers of hexamers were also present in the sample (classes 1, 2, 4, 7 and 9; 515 
Extended Data Fig. 3e) and were likely formed by asymmetrical hexamers as a 516 
consequence of the limiting concentration of detergent used in sample preparation. 517 
2,502,546 particles of SERINC5-Fab complex, autopicked using Gautomatch 518 
(http://www.mrc-lmb.cam.ac.uk/kzhang/), were subjected to reference-free 2D 519 
classification in cryoSPARC. The initial 3D model was obtained using ab initio 520 
reconstruction in cryoSPARC from a subset of particles belonging to 2D classes 521 
displaying clear density attributable to Fab. A total of 1,449,789 particles from well-522 
defined 2D classes were subjected to classification in Relion-3 into eleven 3D classes. 523 
The most populated class containing 270,151 particles displayed high-resolution 524 
features with strong density corresponding to Fab outside and SERINC5 TMs inside 525 
the micelle. These particles were used for 3D auto-refinement in Relion-3 with a soft 526 
mask around the entire particle using C1 symmetry, including the detergent micelle 527 
resulting in a 3D reconstruction to an overall resolution of 8.2 Å and a local resolution 528 
throughout the protein density of 6.5-7 Å  (Extended Data Fig. 2e-g). Resolution is 529 
reported according to the gold-standard Fourier shell correlation (FSC), using the 530 
0.143 criterion37 (Table 1, Extended Data Figs 2f,g and 3f,g). Local resolution was 531 
estimated using blocres tool from BSOFT package 38. 532 
 533 
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Model building and refinement. The DmSERINC model was built ab initio into the 534 
cryo-EM map using Coot39. Initially, poly-Ala α-helices were placed for each of the 535 
10 TM regions in one monomer and bulky side-chain features for aromatic residues 536 
were used to identify the sequence register. Further residues were added manually to 537 
complete one subunit of the hexameric ring, this was then used to generate the 538 
remaining five monomers in the hexamer. The hexameric model was then subjected to 539 
real space refinement using Phenix40,41 with NCS constraints and refining group B-540 
factors (one per residue) and assessed using MolProbity42 and EMringer43. The final 541 
model contains 365 amino acid residues per subunit, lacking N-terminal peptide 542 
(residues 1-29) and portions of ECL1 (residues 75-89), ECL4 (residues 306-321), 543 
ICL4 (residues 354-389), and the C-terminal peptide (residues 462-465) as illustrated 544 
in the topology diagram in Extended Data Fig. 4a. One cardiolipin, two LMNG, and 545 
one PS molecule per monomer were tentatively built into the cryo-EM map and are 546 
included in the co-ordinates. Data statistics are given in Table 1. A homology model 547 
of SERINC5 was assembled based on DmSERINC structure using SWISS-MODEL 548 
server44. Interface surface areas were calculated using the PISA server45, and 549 
membrane buried regions were predicted using the PPM  server46. 550 
 551 
Molecular dynamics. The atomic coordinates of DmSERINC (protein only) were 552 
converted to their Martini CG representation47,48, and built into POPC membranes. 553 
Missing loops were modelled using SWISS-MODEL44, with the loop between TM1 554 
and TM2 modelled as (GlySer)3 hexapeptide, the loop between TM7 and TM8 555 
modelled using the native structure (MFGMMEG), and the loop between TM8 and 556 
TM9 modelled as (GlySer)7. Simulations were run over 100 ns using a 20 fs time-557 
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step, in the NPT ensemble at 323 K with the V-rescale thermostat, and 1 bar using 558 
semi-isotropic Berendsen pressure coupling.  559 
Atomistic simulations were run following conversion of 100 ns CGMD 560 
snapshots in a POPC bilayer. Conversions were carried out using the CG2AT 561 
protocol49, with Charmm36 forcefield50 used to describe the system. Electrostatics 562 
were handled using the Particle-Mesh-Ewald method, and a force-switch modifier 563 
was applied to the Van der Waals forces. Dispersion corrections were turned off. 564 
Simulations were run for ~215 ns with Velocity-rescaling temperature coupling at 310 565 
K using a time constant of 0.1 ps and Parrinello-Rahman semi-isotropic pressure 566 
coupling of 1 Bar with a time constant of 2 ps, using 4 fs time steps with virtual-sites 567 
on the protein and lipids51. All simulations were run in Gromacs 201852; images were 568 
made in VMD53.  569 
 570 
Infectivity assays. The effect of SERINC5 mutants on the infectivity of HIV-1 was 571 
studied using virions limited to a single round of replication. To this end, 200,000 572 
HEK293T cells were transfected with 800 ng of an env-defective and nef-defective 573 
HIV-1NL4-3 provirus construct together with 100 ng of PBJ5-HXB2-Env2 and a 574 
plasmid encoding variants of SERINC5 harbouring an internal FLAG epitope 575 
(DYKDDDDKDI, inserted between residues 290 and 291) and a C-terminal HA tag 576 
(SERINC5-iFLAG, HA), or an appropriate empty vector control using calcium 577 
phosphate. High-level overexpression of SERINC5 results in suppression of viral 578 
release, which is not characteristic of the restriction factor at endogenous levels2. 579 
Therefore, SERINC5 mutants were tested using constructs based on pBJ6 or pBJ5, 580 
both of which harbour a weak promoter, resulting in moderate and low expression 581 
compared to pcDNA, respectively2. All experiments used a matched wild type 582 
 34
SERINC5 control and the constructs and amount of SERINC5 expressing plasmid 583 
used in specific experiments are described in Supplementary Table 2. Virus-584 
containing culture supernatants were collected 48 h after transfection, clarified by 585 
centrifugation at 300g for 5 min and passed through a 0.45-μm filter. Virus in cell 586 
supernatants was quantified using the Sybr Green PCR-enhanced reverse transcriptase 587 
assay25,54, and five serial dilutions were inoculated onto HeLa-TZM-GFP reporter 588 
cells, which contain an integrated reporter gene encoding GFP with a nuclear 589 
localization signal under the transcriptional control of the HIV-1 long terminal 590 
repeat2. Infections were performed in quadruplicate and the number of cells infected 591 
was evaluated using an EnSight plate reader (Perkin Elmer). Infectivity was measured 592 
by normalizing numbers of infected cells according to the reverse transcriptase 593 
activity in each viral preparation. Only dilutions within a linear range were 594 
considered. Reduction of infectivity caused by SERINC5 proteins was then calculated 595 
by dividing the infectivity of viruses produced in the absence of SERINC5 with the 596 
infectivity of viruses produced when co-expressing SERINC5. The residual restriction 597 
activity of each SERINC5 mutant on HIV-1 infectivity was then expressed in relation 598 
to the reduction caused by the wild type protein, considered as 100%. Where error 599 
bars are present, they represent standard error of the mean obtained from three 600 
independent biological triplicates or four technical replicates as indicated. 601 
 602 
Surface exposure of SERINC5 mutants. To investigate SERINC5 expression by 603 
flow cytometry, 200,000 HEK293T cells were co-transfected with DNA constructs 604 
expressing SERINC5-iFLAG-HA variants based on either pcDNA3.1 or pBJ5 vectors 605 
as indicated in Supplementary Table 2 along with 300 ng pIRES2-GFP, to allow for 606 
selective gating of transfected cells, and 1 μg pBluescript. Forty-eight h post-607 
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transfection, cells were collected, washed with ice-cold PBS and fixed with 2% 608 
paraformaldehyde. Each sample was then divided in two, and processed for staining 609 
with anti-FLAG antibody for selective detection of SERINC5 on the cell surface in 610 
non-permeabilized cells or for detection of total SERINC5 expression after 611 
permeabilisation with Wash&Perm solution (Becton Dickinson). SERINC5-iFLAG-612 
HA was detected using mouse M2 anti-FLAG antibody (Sigma) diluted 1:500 and an 613 
APC-conjugated anti-mouse IgG (Jackson Immunoresearch) diluted 1:500. Samples 614 
were analysed using a FACS Canto (Becton Dickinson). SERINC5 expression was 615 
assessed on the live cell population gated on FSC vs SSC, followed by gating the 616 
transfected cell population, which express GFP, as illustrated in Supplementary 617 
Information Table 2. 618 
 619 
SERINC5 incorporation into virus particles and immunoblotting. To detect 620 
SERINC5 associated with virus particles, 5 million HEK293T cells were transfected 621 
with 18 μg env-defective and nef-defective HIV-1NL4-3 provirus construct together 622 
with 2 μg pBJ5-HXB2-Env and 1 μg pBJ5-SERINC5-iFLAG-HA. To verify specific 623 
detection of virus-associated SERINC5, a control sample was produced by 624 
transfecting a Gag-defective HIV-1NL4-3 provirus construct. Cell supernatants from 625 
transfected cells were clarified by centrifugation at 300g for 5 min, passed through 626 
filters with 0.45-μm pores, overlaid on a 25% sucrose cushion and concentrated by 627 
centrifugation for 2 h at 100,000g in a SW41 swingout rotor (Beckman Coulter). The 628 
resulting viral pellets were resuspended in Laemmli sample buffer supplemented with 629 
50 mM TCEP. Virus producing cells were collected in PBS, pelleted and lysed in an 630 
ice-cold buffer containing 100 mM NaCl, 10 mM HEPES pH 7.5, 1% DDM and 631 
protease inhibitors. Lysates, clarified by centrifugation and mixed with Laemmli 632 
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buffer supplemented with 50 mM TCEP, were separated on 12.5% acrylamide Tricine 633 
gels and transferred onto Immobilon-FL PVDF membrane (Millipore). Blots were 634 
probed with mouse anti-HA (clone 16B12, Covance) diluted 1:1,000, rabbit anti-635 
β actin (Li-COR) diluted 1:1,000 and rabbit anti-HIV-1 p24 (ARP432; National 636 
Institute for Biological Standards and Control) antibody. Secondary antibodies were 637 
conjugated to IRDye 680 or IRDye 800 (Li-COR), and blots were imaged using an 638 
Odyssey infrared imaging System (Li-COR). 639 
 640 
HIV-1 neutralization assays. Sensitivity to neutralizing antibodies was measured 641 
using virions limited to a single round of replication produced by transfection of 642 
HEK293T cells similarly to as described for the infectivity assay, with the only 643 
difference that the HIV-1NL4-3 Env defective provirus construct was complemented in 644 
trans with a vector encoding Env derived from HIV-1JRFL (pSV-JRFL), which allows 645 
production of virions minimally sensitive to the effect of SERINC5 on infectivity. 646 
Viruses were normalized based on reverse transcriptase activity and the inocula were 647 
adjusted to produce between 1% and 3% infection of the monolayer. Viruses were 648 
incubated with serially diluted neutralizing antibodies for 1 h at room temperature. 649 
The complexes were added to TZM-bl GFP cells, seeded onto 96-well tissue culture 650 
plates a day prior to neutralization, incubated at 37°C for 2 h, followed by two washes 651 
with PBS before being cultured in fresh complete DMEM. Infected cells were 652 
incubated at 37°C for 42 h before scoring number of infected cells per each well using 653 
an Ensight plate reader.  654 
Neutralization was measured by calculating the residual infectivity of treated 655 
virus samples considering the infectivity of the untreated sample as 100%. Fitted 656 
sigmoidal curves and the IC50 values were obtained using Prism (Graphpad) with the 657 
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least square variable slope method using the dose-normalized response protocol. 658 
Neutralizations were performed in quadruplicate with each combination of virus and 659 
antibody to be analyzed and data shown are the average with the error bars 660 
representing the 95% confidence interval as calculated by Prism. Neutralizing 661 
antibodies 4E10 (ARP3239) and 2F5 (ARP3063) were obtained from the UK 662 
National Institute for Biological Standards and Control.  663 
 664 
Protein thermostability assay. Melting curves were recorded using 20-95°C 665 
1.5°C/min temperature ramps on a Promethius NT.48 instrument with standard 666 
capillaries (Nanotemper). Proteins were diluted to 1 mg/ml in 40 mM NaCl, 10 mM 667 
HEPES-NaOH, pH 7.5, 0.0003% LMNG; where indicated, samples were spiked with 668 
0.1 mM lipid. Lipid stock details are given in Supplementary Note 1. 669 
 670 
Native protein mass spectrometry. Purified DmSERINC was buffer exchanged into 671 
200 mM ammonium acetate, pH7 supplemented with 0.002% LMNG using Bio-Spin 672 
6 Columns (BioRad). Samples were analysed at a final concentration of 5 μM using a 673 
Q-Exactive mass spectrometer (Thermo Fisher Scientific) modified for high 674 
molecular weight ions as previously described55. Cardiolipin (Avanti), PI(3,4)P2 675 
(Avanti), PI(4,5)P2 (Avanti), POPE (Avanti), POPC (Avanti) and POPG (Avanti) 676 
were reconstituted to 3 mM in 200 mM ammonium acetate supplemented with 677 
0.017% DDM and diluted into the desired concentration using 200 mM ammonium 678 
acetate with 0.002% LMNG. Lipids were added to DmSERINC samples and 679 
equilibrated for 20 min prior to analysis. Ions were generated by static nano-680 
electrospray using gold-coated capillaries prepared in-house as described 681 
previously56. Instrument settings were as follows: capillary voltage 1.5 kV, source 682 
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temperature 40°C, S-lens RF = 200, maximum injection time 150, HCD voltage 200 683 
V, desolvation voltage -10 (positive mode), with in-source trapping on. Data were 684 
acquired between 2,000-15,000 with 10 microscans, and results were processed using 685 
XCalibur 2.2 software (Thermo Fisher Scientific). DmSERINC peak assignments 686 
were done manually using in-house software as well as with UniDec software57. 687 
 688 
Lipidomics. Sequencing grade trypsin (Promega) was added to 20 μg DmSERINC 689 
(5:1 SERINC to trypsin) and incubated overnight at 37°C. Samples were dried in a 690 
vacuum concentrator and reconstituted (15 min sonication) in 30 μl acetonitrile:water  691 
(60:40, v/v), 10 mM ammonium formate, 0.1% formic acid (buffer A). Samples were 692 
centrifuged for 3 min at 10,000g and 15 μl was removed for analysis. For each run, 5 693 
μl was injected onto a C18 column (Acclaim PepMap 100, C18, 75 mm × 15 cm; 694 
Thermo Scientific) on a Dionex UltiMate 3000 RSLC nanoLC System. A 32-99% 695 
linear gradient to buffer B (isopropanol:acetonitrile (90:10, v/v), 10 mM ammonium 696 
formate, 0.1% formic acid) was used with a flow rate of 300 nl/min over 30 min. Data 697 
were acquired using an LTQ Orbitrap mass spectrometer (Thermo Fisher Scientific) 698 
in negative ion mode with the following data-dependent acquisition settings: full-scan 699 
mass range 350-2,000 m/z, resolution 60,000, normalized collision energy 38%, 700 
activation time 30 msec, automatic gain control target 30,000, capillary voltage 1.8 701 
kV, and capillary temperature 180°C. Collision-induced dissociation was performed 702 
for the five most intense ions, data were interpreted manually using XCalibur 2.2 703 
software (ThermoFisher Scientific).  704 
 705 
HDX mass spectrometry. Deuterium exchange reactions of DmSERINC 706 
(monomeric fraction) in LMNG micelles with or without addition of exogenous DPPS 707 
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(Echelon Biosciences), sulfatide (Matreya LLC) or PC (Echelon Biosciences), were 708 
initiated by diluting the proteins in D2O (99.8% D2O, Sigma-Aldrich) in 10 mM 709 
HEPES pH 7.5, 40 mM NaCl, 2 mM DTT and 1 mM TCEP to obtain a final D2O 710 
concentration of ~91%. For all experiments, deuterium labelling was carried out at 711 
23°C (unless otherwise stated) at four points, 3, 30, 300, and 3,000 sec in triplicate. 712 
The exchange was quenched by the addition of chilled 2 M guanidinium 713 
hydrochloride in 100 mM phosphate buffer, pH 2.4 (adjusted with formic acid), 15 714 
mM TCEP and 0.1% v/v DDM. Samples, snap frozen in liquid nitrogen, were stored 715 
at -80°C prior to analysis. 716 
 The quenched protein samples were rapidly thawed and subjected to 717 
proteolytic cleavage with pepsin followed by reversed phase chromatography. Briefly, 718 
the protein was passed through a 5-μm 2.1 × 30 mm Enzymate BEH immobilized 719 
pepsin column, (Waters) at 200 μl/min for 2 min; the peptic fragments were trapped 720 
and desalted on a 1.7-μm 2.1 × 5 mm C18 trap column equipped with Acquity BEH 721 
C18 Van-guard pre-column (Waters). Trapped peptides were subsequently eluted 722 
over 11 min with a 3%–43% gradient of acetonitrile in 0.1% v/v formic acid at 40 μ723 
l/min. Peptides were separated on a reverse phase column (Acquity UPLC BEH C18 724 
column 1.7 μm, 100 mm x 1 mm, Waters) and detected on a SYNAPT G2-Si HDMS 725 
mass spectrometer (Waters) over a m/z of 300 to 2000, with the standard electrospray 726 
ionization (ESI) source with lock mass calibration using [Glu1]-fibrino peptide B (50 727 
fmol/μl). The mass spectrometer was operated at a source temperature of 80°C and a 728 
spray voltage of 2.6 kV. Spectra were collected in positive ion mode. Peptide 729 
identification was performed by MSE58 using an identical gradient of increasing 730 
acetonitrile in 0.1% v/v formic acid over 11 min. 731 
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 The resulting MS data were analysed using Protein Lynx Global Server 3.0 732 
software (Waters) with an MS tolerance of 5 ppm. Mass analysis of the peptide 733 
centroids was performed using DynamX 3.0 software (Waters). Only peptides with 734 
scores exceeding 6.4 were considered. The first round of analysis and identification 735 
was performed automatically by the DynamX 3.0 software, however, all peptides 736 
(deuterated and non-deuterated) were manually verified at every time point for the 737 
correct charge state, presence of overlapping peptides, and correct retention time. 738 
Deuterium incorporation was not corrected for back-exchange and represents relative, 739 
rather than absolute changes in deuterium levels. Changes in H/D amide exchange in 740 
any peptide may be due to a single amide or a number of amides within that peptide. 741 
The DynamX 3.0 software plots the standard deviation for every peptide. The error 742 
band shows the standard deviation of the plotted uptake or difference for each 743 
peptide. When there are multiple exposures, as in this experiment, for a given peptide, 744 
the maximum standard deviation is plotted for each peptide. A sigma multiplier of 1 is 745 
applied to the standard deviation to produce the grey error bar plotted in Extended 746 
Data Fig. 7b-e. 747 
 748 
 749 
Data Availability. The cryo-EM maps and the refined atomic model of DmSERINC 750 
were deposited in the EMDB and wwPDB, respectively, with accession codes EMD-751 
10277 and EMD-10279 and PDB 6SP2. Source data for Figures 4a, 4b, 4c, 4e and for 752 
Extended Data Figures 1a, 1c, 1d, 1e, 2b, 3b, 4g-i, 6e-g, are available with the paper 753 
online. 754 
 755 
 756 
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